Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
22 June 2018Website:
http://www.autolus.comNext earnings report:
12 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:57:53 GMTDividend
Analysts recommendations
Institutional Ownership
AUTL Latest News
LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update.
Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights.
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Olivia Manser – Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Asthika Goonewardene – Truist Kelly Shi – Jefferies James Shin – Deutsche Bank Matthew Phipps – William Blair Yanan Zhu – Wells Fargo Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Second Quarter 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded.
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update.
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated with improved event-free survival Autolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below) LONDON, May 31, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces longer-term follow-up and additional data analysis from the pivotal Phase 1b/2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). “At 21 months of median follow up, we're really pleased to be observing the potential for a long-term plateau of survival outcomes with obe-cel in the FELIX trial,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Autolus Therapeutics plc will be presenting additional analyses from the FELIX Phase 2 data at upcoming conferences, with two patients enrolled in the Phase 1 SLE trial. The company is on track to release initial data by the end of 2024. The European Medicines Agency has accepted the Market Authorization Application for obe-cel in r/r adult ALL. A conference call will be held today at 08:30 am EDT/13:30 pm BST, and participants should pre-register using the link provided in the press release. Autolus CEO, Dr. Christian Itin, stated that the company is actively engaging with the FDA in the regulatory review process for obe-cel and preparing for commercial readiness activities.
Autolus Therapeutics plc (NASDAQ:AUTL) is holding a conference call on May 17, 2024 at 8:30 AM ET to discuss its Q1 2024 earnings and business updates. The call will be led by CEO Christian Itin and CFO Rob Dolski, with investor relations represented by Olivia Manser. Various analysts from firms such as Jefferies, Deutsche Bank, and Needham & Company will also be participating in the call. The call is being recorded for reference.
Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several strong leadership hires with direct experience in M&A, oncology, and lupus, a new research area.
Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL with reduced toxicities compared to other CAR T-cell therapies. Autolus Therapeutics also has a dual-targeted BCMA/CD19 CAR T-cell therapy called AUTO8, which has shown positive responses in patients with relapsed/refractory multiple myeloma.
What type of business is Autolus Therapeutics?
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
What sector is Autolus Therapeutics in?
Autolus Therapeutics is in the Healthcare sector
What industry is Autolus Therapeutics in?
Autolus Therapeutics is in the Biotechnology industry
What country is Autolus Therapeutics from?
Autolus Therapeutics is headquartered in United Kingdom
When did Autolus Therapeutics go public?
Autolus Therapeutics initial public offering (IPO) was on 22 June 2018
What is Autolus Therapeutics website?
https://www.autolus.com
Is Autolus Therapeutics in the S&P 500?
No, Autolus Therapeutics is not included in the S&P 500 index
Is Autolus Therapeutics in the NASDAQ 100?
No, Autolus Therapeutics is not included in the NASDAQ 100 index
Is Autolus Therapeutics in the Dow Jones?
No, Autolus Therapeutics is not included in the Dow Jones index
When was Autolus Therapeutics the previous earnings report?
No data
When does Autolus Therapeutics earnings report?
The next expected earnings date for Autolus Therapeutics is 12 November 2024